INS and early-onset autosomal dominant Alzheimer disease: This approach could therefore be used to target numerous receptors, such as insulin, neuronal nicotinic acetyl choline, vascular endothelial growth factor receptors, etc., for the treatment of diseases, like diabetes, Alzheimer’s disease, schizophrenia and tumors.